Fig. 1
From: Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
Effect of the different HDACi, in combination or not with decitabine, on lymphocytes and T-cell clones viability. Lymphocytes (Lc) and T-cell clones (Clone) were treated with increasing concentrations of VPA (a), SAHA (b), ODB (c), NODB (d), ODH (e), and NODH (f) for 72 h, in combination or not with decitabine (5-aza) 500 nM (72 h pretreatment). Viability was measured using Cell Titer-Glo kit. Results are expressed as the means ± S.E.M of three independent experiments